<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&lt;table id="schedule" cellspacing="0" cellpadding="2" summary="This table shows the date, time, and location of the meeting" border="0" sizcache="12" sizset="0"&gt;&lt;tbody sizcache="11" sizset="0"&gt;&lt;tr id="rrtr0"&gt;&lt;th id="a1" valign="top" align="left" bgcolor="#cccccc"&gt;Center&lt;/th&gt;&lt;th id="a2" valign="top" align="left" bgcolor="#cccccc"&gt;Date&lt;/th&gt;&lt;th id="a3" valign="top" align="left" bgcolor="#cccccc"&gt;Time&lt;/th&gt;&lt;th id="a4" valign="top" align="left" bgcolor="#cccccc"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr id="rrtr1"&gt;&lt;td id="rrtd0" valign="top" headers="a1" height="61"&gt;CDRH&lt;/td&gt;&lt;td id="rrtd1" valign="top" headers="a2"&gt;October&amp;nbsp;24, 2012&lt;br /&gt;&amp;nbsp;&lt;/td&gt;&lt;td id="rrtd2" valign="top" headers="a3"&gt;8:00 a.m. to 6:00 p.m.&lt;br /&gt;&amp;nbsp;&lt;/td&gt;&lt;td id="rrtd3" valign="top" headers="a4"&gt;&lt;p&gt;Hilton Washington DC North/Gaithersburg, &lt;br /&gt;Salons A, B, C, and D,&lt;br /&gt;620 Perry Pkwy., &lt;br /&gt;Gaithersburg, MD 20877.&amp;nbsp;&lt;br /&gt;The hotel&amp;rsquo;s telephone number is 301-977-8900.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/p&gt;&lt;div&gt;&lt;b&gt;&lt;font size="3"&gt;Agenda&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;On October 24, 2012, the committee will discuss, make recommendations, and vote on a premarket approval application supplement to expand the indications for use of the Selenia Dimensions 3D System with C-View Software Module, sponsored by Hologic, Inc.&lt;/div&gt;&lt;div&gt;The Selenia Dimensions 3D System is currently approved for breast cancer screening and diagnosis. The screening exam can consist of field digital mammography (FFDM) alone or the combination of FFDM with digital breast tomosynthesis (DBT).&lt;/div&gt;&lt;div&gt;The new C-View Software Module can generate synthetic 2D images from the DBT data. Hologic requests to expand the indications for use to allow the combination of DBT with synthetic 2D images to be used as another exam option for breast cancer screening.&lt;/div&gt;&lt;div&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting.&amp;nbsp;If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting.&amp;nbsp;Background material is available at&amp;nbsp;&lt;a href="http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/default.htm"&gt;http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/default.htm&lt;/a&gt;. Scroll down to the appropriate advisory committee meeting link.&lt;br /&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;b&gt;&lt;font size="3"&gt;Meeting Materials&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;&lt;div&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&amp;nbsp;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;b&gt;&lt;font size="3"&gt;Public Participation Information&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&amp;nbsp;Written submissions may be made to the contact person on or before October 15, 2012.&amp;nbsp;Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m.&amp;nbsp;Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before October 5, 2012.&amp;nbsp;Time allotted for each presentation may be limited.&amp;nbsp;If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.&amp;nbsp;The contact person will notify interested persons regarding their request to speak by October 9, 2012.&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.&lt;/div&gt;&lt;div&gt;FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact James Clark, Conference Management Staff, at &lt;u&gt;&lt;a href="mailto:James.Clark@fda.hhs.gov"&gt;James.Clark@fda.hhs.gov&lt;/a&gt;&lt;/u&gt; or 301-796-5293, at least 7 days in advance of the meeting.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;b&gt;&lt;font size="3"&gt;Contact Information&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;&lt;ul sizcache="5" sizset="29"&gt;&lt;li sizcache="1" sizset="39"&gt;&lt;div&gt;Shanika Craig, &lt;br /&gt;Center for Devices and Radiological Health, &lt;br /&gt;Food and Drug Administration, &lt;br /&gt;10903 New Hampshire Ave., &lt;br /&gt;Bldg. 66, rm. 1613, &lt;br /&gt;Silver Spring, MD&amp;nbsp;20993, &lt;br /&gt;&lt;u&gt;&lt;a href="mailto:Shanika.Craig@fda.hhs.gov"&gt;Shanika.Craig@fda.hhs.gov&lt;/a&gt;&lt;/u&gt;, &lt;br /&gt;301-796-6639&lt;/div&gt;&lt;/li&gt;&lt;/ul&gt;&lt;ul sizcache="5" sizset="30"&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington DC area)- follow the prompts to the desired center or product area&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;div&gt;&lt;br /&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div sizcache="1" sizset="40"&gt;FDA is committed to the orderly conduct of its advisory committee meetings.&amp;nbsp;Please visit our Web site at &lt;a href="http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm"&gt;http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/div&gt;&lt;div sizcache="1" sizset="41"&gt;&amp;nbsp;&lt;/div&gt;&lt;div sizcache="1" sizset="41"&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/div&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
